ClinicalTrials.gg
Not yet recruitingNCT07540611GTIHNOUpdated Nov 17, 2026

Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive

An interventional study of No intervention and hCG + FSH therapy in APHRODITE Group, sponsored by Indira IVF Hospital Pvt Ltd. Not yet recruiting at 8 sites in India. Open to male participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Indira IVF Hospital Pvt Ltd · Not applicable, Interventional, and Treatment

How we know · 2 judgments

Updated Nov 17, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
860
Allocation
Randomized
Sex
Male
01

Study summary

The goal of this clinical trial is to determine whether short-term gonadotropin therapy (hCG + FSH) can increase sperm availability for ICSI in men with idiopathic non-obstructive azoospermia (NOA) and hypogonadism. The main questions it aims to answer are:

Does hormonal optimization improve the likelihood of obtaining usable sperm (via ejaculate or micro-TESE) by Week 16? Does hormonal therapy reduce the need for micro-TESE or improve downstream embryological and clinical outcomes?

Because there is a comparison group, researchers will compare hCG + FSH hormonal therapy with standard-of-care (no gonadotropins) to see if hormonal optimization increases sperm retrieval success and decreases surgical reliance.

Participants will:

Undergo baseline hormonal and semen testing Be randomized to either hormonal therapy or standard-of-care If in the hormonal arm: receive hCG and FSH with monthly dose titration and aromatase inhibitors if indicated Provide semen samples at Weeks 12 and 16 Undergo micro-TESE if no ejaculated sperm are found (timing per protocol) Complete safety assessments and follow-up through Week 16

02

Conditions studied

  • APHRODITE Group

Keywords

  • Non-obstructive azoospermia (NOA)
  • Idiopathic NOA
  • Male infertility
  • Hypogonadism
03

In context

Infertility, Male

283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.

This study's planned enrollment of 860 is above the median of 80 across 188 interventional studies indexed under Infertility, Male.

Browse Infertility, Male studies →

Lead sponsor

Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Idiopathic NOA; hypogonadal (TT \<350 ng/dL on two fasting morning tests); FSH ≥7.6 IU/L (APHRODITE Group 3: 7.6-12.0 IU/L; Group 4: >12.0 IU/L).

Exclusion criteria

Exclusion Criteria:

cryptorchidism, chemo/radiation, genetic NOA (e.g., AZFa/complete AZFb), testicular trauma/torsion, post-orchitis. prior micro-TESE within 12 months; recent gonadotropin therapy (\<6 months); uncontrolled endocrine disease; active ; severe liver disease; polycythemia (Hct>50%); inability to comply. Varicocele>= Grade 3

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
860 participants (estimated)

Study arms

  • Experimental
    hCG + FSH therapy

    Other: hCG + FSH therapy

  • Active comparator
    Standard of Care

    Other: No intervention

Interventions

  • OtherNo intervention

    Standard of Care

  • OtherhCG + FSH therapy

    hCG + FSH therapy with monthly hormone-driven titration (hCG initial \~83 µg SC twice weekly; no preset min/max; target TT \>350-900 ng/dL) + FSH 150 IU SC twice weekly (increase to 150 IU SC three times weekly if 'FSH reset' \<1.5 IU/L); allow anastrozole 1 mg PO daily /letrozole 2.5 mg half tablet alternate day if T/E \<10

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Success or Sperm Availability

    Sperm Availability for ICSI was defined as the presence of viable sperm suitable for intracytoplasmic sperm injection (ICSI) at any time from randomization through Week 16. Sperm could be obtained either through ejaculate or via microsurgical testicular sperm extraction (micro-TESE). Assessment of sperm availability was performed by a centralized adjudication committee, which was blinded to treatment allocation to ensure objective and unbiased evaluation.

    Time frame: from randomization through Week 16 via ejaculate or micro-TESE

Secondary outcomes

  1. Micro-TESE Sperm Retrieval Rate (SSR)

    Whether sperm are retrieved during micro-TESE

    Time frame: The Micro-TESE Sperm Retrieval Rate (SSR) was assessed during the period from randomization through Week 16. The outcome was determined based on the availability of at least one viable sperm retrieved via microsurgical testicular sperm extraction (micro-

  2. Need for Micro-TESE Surgery

    Whether the participant requires micro-TESE

    Time frame: Up to Week 16

  3. Safety / Harms

    All adverse events (AE/SAE) related to treatment or procedure

    Time frame: Week 16

  4. ICSI Fertilization Rate

    % of injected oocytes that form normal 2PN embryos

    Time frame: Within the ICSI cycle ≈ Day 1-3 after ICSI

  5. Blastulation Rate

    % of embryos reaching blastocyst stage

    Time frame: Day 5-7 after fertilization

  6. Blastocyst Quality

    Grading of blastocysts based on standard morphology criteria

    Time frame: Day 5-7 after fertilization

  7. Top-Quality Blastocyst Rate

    % of "top-1 quality" blastocysts formed

    Time frame: Day 5-7 after fertilization

  8. Clinical Pregnancy Rate

    Presence of gestational sac with cardiac activity on ultrasound

    Time frame: ≈ 6-8 weeks after embryo transfer

  9. Miscarriage Rate

    Pregnancy loss before 20 weeks

    Time frame: From pregnancy confirmation to 20 weeks gestation

  10. Live Birth

    Delivery of a live infant

    Time frame: Up to delivery (~9 months after embryo transfer)

07

Study locations

8 sites
08

References and documents

Publications

  • Esteves SC, Yarali H, Vuong LN, Carvalho JF, Ozbek IY, Polat M, Le HL, Pham TD, Ho TM. Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients. Front Endocrinol (Lausanne). 2021 Mar 12;12:630550. doi: 10.3389/fendo.2021.630550. eCollection 2021. PubMed 33790862 ↗
  • Esteves SC, Humaidan P, Ubaldi FM, Alviggi C, Antonio L, Barratt CLR, Behre HM, Jorgensen N, Pacey AA, Simoni M, Santi D. APHRODITE criteria: addressing male patients with hypogonadism and/or infertility owing to altered idiopathic testicular function. Reprod Biomed Online. 2024 Apr;48(4):103647. doi: 10.1016/j.rbmo.2023.103647. Epub 2023 Oct 29. PubMed 38367592 ↗
  • Chandra V, Esteves SC, Sanagoudar S. Gonadotropin therapy in idiopathic hypogonadal non-obstructive azoospermia (APHRODITE Groups 3-4): a multicenter randomized controlled trial. Front Reprod Health. 2026 Jul 9;8:1867412. doi: 10.3389/frph.2026.1867412. eCollection 2026. PubMed 42495163 ↗

Individual participant data

Plan to share: Undecided — will be shared on request

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Nov 2027, 9 months later.

Of 78 non-industry interventional studies with no phase under Infertility, Male, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 9 months is below that.

Counting every sponsor, half of 93 studies reached it within 34 months; a quarter within 17 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Jul 2026 → Jan 2027, primary completion Jan 2027 → Nov 2027 and completion Jul 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Apr 20, 2026
StartEst.
Jan 17, 2027was Jul 2026
Primary completionEst.
Nov 16, 2027was Jan 2027
CompletionEst.
Jun 17, 2028was Jul 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 17, 2026→Jan 17, 2027
Nov 17, 2026
Primary completion
Jan 16, 2027→Nov 16, 2027
Nov 17, 2026
Study completion
Jul 17, 2027→Jun 17, 2028
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Jul 17, 2026→Jan 17, 2027
    Primary completion Jan 16, 2027→Nov 16, 2027
    Study completion Jul 17, 2027→Jun 17, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07540611
Lead sponsor
Indira IVF Hospital Pvt Ltd
Responsible party
Dr Vipin Chandra (Chief Clinical Lab Operations, Indira IVF Hospital Pvt Ltd) — Principal investigator
First posted
Apr 20, 2026
Start date
Jan 17, 2027 (estimated)
Primary completion
Nov 16, 2027 (estimated)
Completion
Jun 17, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Vipin Chandra, DGO
Contact
drvipinchandra@indiraivf.in
9567971239

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion